Lenalidomid Alkaloid-Int

Lenalidomide, the active ingredient in Lenalidomid Alkaloid-Int, is an immunomodulatory imide drug (IMiD) presented as an oral formulation for oral use. It treats multiple myeloma, mantle cell lymphoma, and myelodysplastic syndromes with 5q deletion in adult patients.

GNH USA supplies Lenalidomid Alkaloid-Int as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, ensuring consistent quality, regulatory compliance, and reliable logistics for oncology therapeutics. The company adheres to stringent Good Distribution Practice standards and provides comprehensive support for product registration, customs clearance, and cold‑chain management where required.

Lenalidomide is employed in hematologic malignancies and related myelodysplastic conditions.

- Multiple myeloma: improves progression‑free survival and overall response rates in relapsed or refractory disease. - Mantle cell lymphoma: induces tumor regression and prolongs remission when combined with standard chemotherapy. - Myelodysplastic syndromes with 5q deletion: corrects ineffective hematopoiesis and reduces transfusion dependence.

Lenalidomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Fatigue - Diarrhea - Rash - Constipation

Serious or Rare Side Effects: - Thromboembolic events such as deep‑vein thrombosis or pulmonary embolism - Severe neutropenia or leukopenia - Teratogenic effects leading to fetal harm

Key precautions should be observed when prescribing lenalidomide to minimize risks.

- Pregnancy: contraindicated; category X, avoid use in pregnant women. - Thrombosis risk: assess patient history and consider prophylactic anticoagulation. - Hematologic monitoring: perform regular CBC to detect neutropenia or anemia. - Renal impairment: adjust therapy and monitor renal function. - Drug interactions: avoid concomitant use with strong CYP3A4 inducers without supervision. - Store at ambient temperature: keep below 25°C in original container, protect from moisture.

Lenalidomide can interact with several medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce lenalidomide exposure. - Anticoagulants (warfarin): increased risk of bleeding when combined with lenalidomide. - Immunosuppressants (e.g., cyclosporine): heightened risk of severe cytopenias.

Moderate Interactions (Monitor Closely): - P‑glycoprotein inhibitors (e.g., verapamil): may increase plasma levels. - NSAIDs: may exacerbate thrombocytopenia. - Hormonal contraceptives: reduced efficacy, advise alternative non‑hormonal methods.